Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labelling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES). The Resolute Onyx DES is the first-and-only DES in the USA that has been proven safe and effective utilising a one-month regimen of DAPT—the combination of aspirin and an anticoagulant—following a percutaneous coronary intervention (PCI) in patients at high bleeding risk.
Patients that are at risk for high bleeding include older patients, those with history of bleeding, or those on oral blood-thinning drugs, and account for up to 40% of PCI patients. Clinical studies have demonstrated that Resolute Onyx DES and its biocompatible polymer and stent design promote fast vessel healing and is well-suited for patients who may benefit from a DAPT duration as short as one month.
“It is so rewarding to see the efforts of those involved in examining the safety and efficacy of one-month of DAPT following PCI—the coordinators, investigators and most importantly the Onyx One Clear patient participants—come to fruition with this new high bleeding risk indication for the Resolute Onyx drug eluting stent,” said Ajay Kirtane, professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, New York, USA) and principal investigator for the Onyx One Clear study. ”It is remarkable how the combination of technology innovation, in conjunction with the generation of clinical evidence, has informed our understanding that shorter durations of DAPT may in fact be safe in appropriately selected patients treated with Resolute Onyx DES.”
Using a broad criteria for HBR, the approval is based on results from the Onyx ONE Clear Study that evaluated approximately 1,500 complex HBR patients on one-month DAPT treated with Resolute Onyx. At one year, the study met its primary endpoint of cardiac death or myocardial infarction and showed Resolute Onyx to be safe and effective in HBR patients on one-month DAPT. Results from the study were shared virtually in March at the American College of Cardiology together with the World Congress of Cardiology Scientific Sessions (ACC.20/WCC). The Onyx ONE Clear study, coupled with the Onyx ONE Global study, make up the Onyx ONE Month DAPT Program that supports the advancement of DAPT evidence, initiated by physicians and Medtronic.
“The journey leading to an HBR indication has included years of rigorous clinical evaluation with more than 22,000 complex patients studied,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. “We are excited to realise our goal of providing physicians with more robust data and a supporting indication to inform treatment decisions for HBR patients, who may be suitable for a one-month course of DAPT.”
